Seeking Alpha

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...
Nasdaq

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

Myriad Genetics, Inc. MYGN recently announced a collaboration with GSK plc GSK to advance in the field of genetic testing. The latest development is intended to improve access to homologous ...
News Medical

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...
Business Insider

NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate CancerProlaris®, myRisk® Hereditary Cancer, and myChoice® HRD Testing Are Appropriate For a Total of 200,000 ...

SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for ...

Zydus ties up with US-based Myriad Genetics to launch cancer-risk assessment diagnostic tests in India

Zydus partners with Myriad Genetics to introduce advanced cancer-risk assessment tests, enhancing precision diagnostics in India.
Nasdaq

Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement

Myriad Genetics, Inc. MYGN recently announced the receipt of additional reimbursement in Japan for its myChoice Diagnostic System. Notably, the test aids in identifying patients with advanced ovarian ...